VBI Vaccines Announces Completion of Sales Process to K2
VBI Vaccines Inc. ("VBI" or the "Company") today announced, that, in connection with its creditor protection proceedings under the Companies' Creditors Arrangement Act (Canada) (the "CCAA") and its ...
The Business Journals8d
Durham firm acquires hepatitis B drug from defunct company
A biotechnology firm in Durham is expanding its portfolio with an $18 million deal. STORY HIGHLIGHTS Brii Biosciences ...
VBI Vaccines Restructures and Acquired by K2 VBI Trust
VBI Vaccines ( (VBIVQ) ) has shared an announcement.
Business Wire1mon
VBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company Operations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (VBI) is initiating a voluntary nationwide recall of all remaining PreHevbrio ® [Hepatitis B Vaccine (Recombinant); NDC 75052-001-10 ...
FierceBiotech8d
BeiGene, Brii and Ideaya ring in 2025 with deal news, betting billions in biobucks on prospects
Dealmakers at BeiGene, Brii Biosciences and Ideaya Biosciences had a busy end to the year, sharing news of agreements for ...
Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study
Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical ...